Functional Assessment of TSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex

Authors

Errata

This article is corrected by:

  1. Errata: Functional Assessment of TSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex Volume 34, Issue 2, 409–410, Article first published online: 7 January 2013

  • Contract grant sponsors: The U.S. Department of Defense Congressionally-Directed Medical Research Program (grant TS060052); The Tuberous Sclerosis Alliance; Stichting Michelle.

  • Communicated by George P. Patrinos

Correspondence to: Mark Nellist, Department of Clinical Genetics, Erasmus Medical Centre, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. E-mail: m.nellist@erasmusmc.nl

ABSTRACT

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in the TSC1 or TSC2 genes. The TSC1 and TSC2 gene products, TSC1 and TSC2, form a complex that inhibits the mammalian target of rapamycin (mTOR) complex 1 (TORC1). Here, we investigate the effects of 78 TSC2 variants identified in individuals suspected of TSC, on the function of the TSC1–TSC2 complex. According to our functional assessment, 40 variants disrupted the TSC1–TSC2-dependent inhibition of TORC1. We classified 34 of these as pathogenic, three as probably pathogenic and three as possibly pathogenic. In one case, a likely effect on splicing as well as an effect on function was noted. In 15 cases, our functional assessment did not agree with the predictions of the SIFT amino acid substitution analysis software. Our data support the notion that different, nonterminating TSC2 mutations can have distinct effects on TSC1–TSC2 function, and therefore, on TSC pathology.

Ancillary